Yet another showdown over the high cost of medicines is taking place in Ireland, where the government and the maker of a cystic fibrosis treatment are locked in a battle that has enraged and worried patients.

The struggle is over Orkambi, a drug sold by Vertex Pharmaeuticals that has a price tag of about $170,000 a year. But Ireland’s National Centre for Pharmacoeconomics determined the medicine would be cost effective only if it were priced at about $32,000 per patient and did not recommend reimbursement. Consequently, Ireland’s Health Service Executive has so far refrained from providing coverage.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy